MK-2206 2HCl

Catalog No.S1078

MK-2206 2HCl Chemical Structure

Molecular Weight(MW): 480.39

MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2.

Size Price Stock Quantity  
In DMSO USD 220 In stock
USD 110 In stock
USD 170 In stock
USD 370 In stock
USD 570 In stock
Bulk Discount
Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 183 Publications

21 Customer Reviews

  • Inhibition of AKT signaling abolishes MKK4 phosphorylation on Ser78 in injured axons. Cultures of sensory neurons were treated with 5 µM MK-2206 or 5 µM GDC-0068 for 1 hr prior to axotomy. Axonal proteins harvested at indicated time points after axotomy were subjected to immunoblot analysis.

    Cell, 2015, 160(1-2): 161-76 . MK-2206 2HCl purchased from Selleck.

    j,k, Gene expression ofMYOCD (j) and ACTA2 ( SMA, k) after applying inhibitors of key components involved in the DDR2 downstream signalling pathway to HSCs cultured within 3D collagen matrix subjected to stretching (ST) (n=3, one-way ANOVA, **P=0.0036, ****P<0.0001). l,m, Expression of SMA was significantly reduced after treatment with related inhibitors in early-stage FμNs. (n=4, one-way ANOVA, ***P=0.001, ****P<0.0001). AKT-i: MK-2206

    Nature Materials, 2017, 16:1252-1261.. MK-2206 2HCl purchased from Selleck.

  • The PI3K or AKT inhibition does not restore sensitivity to WZ4002 in PC9 WZR. PC9GR4 or WZR10 cells were treated with WZ4002 alone at the indicated concentrations or in combination with the AKT inhibitor MK-2206 (1 uM). MK-2206 effectively inhibited AKT in both cells.

    Cancer Discov 2012 2, 934-47. MK-2206 2HCl purchased from Selleck.

    Cancer Cell 2013 24, 766-76. MK-2206 2HCl purchased from Selleck.

  • VE-cadherin-induced Akt activation mediates YAP phosphorylation and translocation in ECs. HUVECs were starved for 1h and treated with thrombin (1U) for 1h. Total cell lysates were probed with anti-pAkt, Akt or b-actin antibody. The representative blots of three independent experiments are depicted, and the normalized values for p-Akt are shown. HUVECs were cultured and starved as described as in d and incubated for 8h in complete medium with the Akt inhibitor, MK-2206 (1 uM). pAkt, Akt, pYAP and YAP were detected by western blotting using specific antibodies.

    Nat Commun 2015 6:6943. MK-2206 2HCl purchased from Selleck.

    Rap1b negatively regulates neutrophil transcellular migration by limiting PI3K-Akt signaling. (A-D) Effect of Akt inhibitor MK2206 (2 uM), Src inhibitor PP2 (10 uM), or vehicle control (DMSO) on WT or Rap1b-/- neutrophil functions. (A) Percentage of neutrophil transendothelial migration in 3D migration model. (B) ECM degradation assessed on Oregon green-labeled gelatin matrix; (left) representative images on (bar, 10 um) and (right) bar graph is percentage of matrix degradation. (C) Percentage of cells forming multiple protrusions. (D) Percentage of neutrophils present at junction of activated bEND.3 in 3D migration assay. Mean ?SD; n = 3 independent experiments. **, P < 0.01; ***, P < 0.001; NS, not significant using unpaired Student's t test).

    J Exp Med 2014 211(9), 1741-58. MK-2206 2HCl purchased from Selleck.

  • Inhibitors of AKT or ERK overcome SDF-1a-mediated resistance to ibrutinib-triggered PARP and caspase 3 cleavage in CXCR4S338X-expressing BCWM.1 cells. CXCR4S338X-expressing WM cells were treated with ibrutinib (0.5 uM) alone or in the presence of SDF-1a (20 nM) and/or the AKT inhibitors MK-2206 (0.5 uM) and AZD-5363 (0.5 uM); or the MEK inhibitors AS-703026 (0.25 uM), AZD-6244 (0.5 uM) and UO126 (5.0 uM). (a) Immunoblotting results for phosphoAKT (S473) and phospho-ERK (T202/Y204) in CXCR4S338X-expressing BCWM.1 cells pretreated with ibrutinib with and without AKT or ERK inhibitors, then subjected to SDF-1a stimulation for 2 min. The inhibitory effect of AZD-5363 on AKT, which is known to paradoxically hyper-phosphorylate pAKT(S473) was confirmed by inhibition of the phospho-activity for the downstream AKT targets glycogen synthase kinase 3b and pS6. (b) Immunoblotting results for cleaved PARP and cleaved caspase 3 in CXCR4S338X-expressing BCWM.1 cells treated with ibrutinib and/or AKT or ERK inhibitors for 6 h at IC50 doses. GAPDH, glyceraldehyde 3-phosphate dehydrogenase.

    Leukemia 2015 29(1), 169-76. MK-2206 2HCl purchased from Selleck.

    Induction of apoptosis positively correlates with FOXO3a protein levels and phosphorylation. (a) Treatment of 11 cell lines seeded in 6-well plates with 8 μM MK-2206 or DMSO for 48 hours. Nuclei were harvested for PI staining and FACS analysis and the differences between drug and no drug are displayed as in Figure b. Both conditions were performed in triplo for each cell line. Below the FACS data is a we stern blot of cell lysates from this panel treated with 8 μM MK-2206 or DMSO and harvested at 24 hours. Each cell line name corresponds to the two western lanes below it and the four cell cycle bars above it.

    Cancer Res 2013 73, 2189-98. MK-2206 2HCl purchased from Selleck.

  • Mean IL-8 concentrations determined by ELISA of the supernatants of HeLa cells infected with wild-type Salmonella. Kinase inhibitors are indicated on the x axis, and the target families of the inhibitors are indicated above each column. CEC, chelerythrine; Pim Inh, Pim-1 inhibitor 2. Inhibitors that significantly affected IL-8 production relative to the control (P < 0.05, Bonferroni post hoc test from one-way ANOVA) are indicated with an asterisk. Relative cell viability is also shown, as determined by reduction of XTT by viable cells. A450, absorbance at 450 nm.

    Sci Signal 2011 4, rs9. MK-2206 2HCl purchased from Selleck.

    Reducing cellular levels of PtdIns5P by overexpression of PIP4Kα inhibits clonogenic growth of U2OS but enhances cell survival in response to H2O2 stimulation. A) U2OS cells (1000) were plated, allowed to attach overnight, and then treated with DMSO (control), PI-103 (0.5 μM), U0126 (5 μM), or SB203580 (5 μM) for 9 d. Cell colonies were stained using crystal violet. Dried plates were scanned. Representative results are shown. B) U2OS cells (1000) were plated, allowed to attach overnight, and then treated with DMSO (control), MK-2206 (1 μM), triciribine (1 μM), KU0063794 (1 μM), or PI-103 (0.5 μM) for 9 d. Cell colonies were stained using crystal violet. Dried plates were scanned. Representative results are shown.

    FASEB J 2013 27, 1644-56. MK-2206 2HCl purchased from Selleck.

  • A. Western blot analysis of pAKT activation in ovarian cancer cell lines treated with exogenous IGF-1. B. Activation of pAKT by IGF-1 in low-grade ovarian cancer cell lines was blocked by the AKT inhibitor MK-2206 in a dose-dependent manner.

    Gynecol Oncol 2011 123, 13-8. MK-2206 2HCl purchased from Selleck.

    Comparative effects of inhibitors by immunofluorescence microscopy study. Confluent HC11 cells were grown on poly-L-lysine-coated glass coverslips (immunofluorescence) and on plastic plates (biochemical control) and then treated with inhibitors according to the standard procedure. Upper part: the biochemical action of the inhibitors was tested to validate the immunofluorescence results. Cellular proteins were analyzed by SDS-PAGE and the immunoblots were successively probed with anti-ADRP, anti-β-casein, and anti- β-actin antibodies and their respective HRP-conjugated secondary antibodies. Each experimental condition was performed in duplicate. Lower part: cells were fixed, permeabilized and subjected to immunofluorescence microscopy using antiserum against ADRP and TRITC-conjugated secondary antibody (red).

    Biochim Biophys Acta 2012 1823, 987-96. MK-2206 2HCl purchased from Selleck.

  • Confocal microscopy images of NO formation. DAF 2 DA-loaded washed platelets (1.0109 platelets/mL) were preincubated at 378C with saline (A), and then stimulated for 1min with 0.1 (B), 1.0 (C) or 10 (D) μM AEA. In Panel (E-F-G) washed platelets were preincubated with 1 μM SR1 (E), 1 Mm MK2206 (F) or 20 μM LY294002 (G), and then stimulated for 1min with 1.0 μM AEA. In panel (H) is reported the effect of 5 mg/mL collagen, used as a positive control. All the experiments were carried out in the presence of 100 μM L-arginine. NO formation was visualized by confocal microscropy as detailed in Methods.

     

     

    J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck.

    The AEA effect on eNOS phosphorylation. Washed platelets (1.0109 platelets/mL), preincubated at 378C with saline, 1 μM SR1, 1 μM SR2, 20 μM LY294002, 1 μM MK2206, 1.0 μM EGTA, or 30 μM BAPTA/AM, were stimulated for 1 min with 1.0 μM AEA. At the end of incubation suitable aliquots were immunoblotted with anti-p-eNOSser1177 as detailed in Methods.Blots are representative of five independent experiments.

     

     

    J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck.

  • Effect of selected agents on NOx and cGMP formation induced by AEA. Washed platelets (1.0109 platelets/mL), prewarmed at 378C with saline or 1mM SR1, 1 μM SR2, 20 μM URB597 (URB), 1 μM MK2206 (MK) or 20 μM LY294002 (LY), were incubated for 1min with 100 μM L-arginine in the presence of 1.0 μM AEA. NOx (panel A) and cGMP (panel B) content were determined as detailed in Methods. Each bar represents the meanSD of five independent experiments carried out in triplicate. Student,s t-test: P <0.0001 versus none;P <0.0005; P <0.005 versus AEA

     

     

    J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck.

    C.U87MG cells were treated with vehicle or 1 μM MK-2206 for 1 hr, and then irradiated with 6 Gy. Total cell lysate was harvested 1 hr after IR and subjected to Western blot analysis with the indicated antibody. Cells without IR treatment were used as a control.

    D. Cells were treated with vehicle (control) or 1 μM MK-2206 for 1 hr, then irradiated with indicated dosage. 4 hr after IR, cells were fed with drug-free medium, and incubated for another 20 hr at 37°C, after which they were trypsinized and seeded for clonogenic survival assay. Colony-forming efficiency was determined 14 d later.
     

     

    Radiat Oncol 2009 4, 43. MK-2206 2HCl purchased from Selleck.

  • (B) Dose-response curves for DIPG 4 and SF7761 cells treated with the small molecule AKT inhibitor MK-2206 (error bars represent SEM).

    Oncol Rep, 2018, 39(2):455-464. MK-2206 2HCl purchased from Selleck.

    MK-2206 2HCL inhibited the sorafenib-induced PI3K/mTOR pathway activation and enhanced the cytotoxic effects of sorafenib in resistant cell lines. (A) HUH-7 hepatoma cells treated with sorafenib (5 μM) for 24 h with or without pretreatment with specific kinase inhibitors (MK-2206 2HCL, 15 μM). The expressions of p-AKT and cleaved PARP were revealed by Western blotting. (B) SK-HEP-1 hepatoma cells treated with sorafenib (5 μM) for 24 h with or without pretreatment with specific kinase inhibitors (MK-2206 2HCL, 15 μM). The expressions of p-AKT and cleaved RARP were revealed by Western blotting. (C) HUH-7 hepatoma cells treated with sorafenib (5 μM) with or without the kinase inhibitors for 24 h. The proportions of apoptotic cells were evaluated by annexin V labeling. (D) SK-HEP-1 hepatoma cells treated with sorafenib (5 μM) with or without the kinase inhibitors for 24 h. The proportions of apoptotic cells were evaluated by annexin V labeling. (*P < 0.05, HUH-7, SK-HEP-1 are control groups, R-HUH-7, R-SK-HEP-1 are resistant groups).

    J Surg Res, 2016, 206(2):371-379. MK-2206 2HCl purchased from Selleck.

  • IC50 values for an Akt inhibitor (MK-2206) and a MEK inhibitor (U0126) in a panel of mouse and human anaplastic (ATC) and follicular (FTC) carcinoma cell lines. On the bottom, a Western blotting showing the effect on the activation of Akt and ERK1/2 of one hour exposure to these inhibitors (MK-2206: 500 nM, U0126: 10 μM).

    Oncotarget 2011 2, 1109-26. MK-2206 2HCl purchased from Selleck.

    After starved in serum-free medium for 24h, Breast cancer cells incubated with the indicated concentrations of MK-2206 for 3h,followed by 15-minute stimolation of 100ng/ml EGF.

     
     

     

    Dr. Zhang of Tianjin Medical University. MK-2206 2HCl purchased from Selleck.

  •  

    PI3K pathway signaling in GDC-0941 and MK-2206 treated MCF-7 derivatives with PIK3CA or  AKT1 mutations. Cells were grown in medium containing 5% FBS and treated with vehicle or increasing concentrations of GDC-0941 (0 nM, 50 nM, 100 nM, and 400 nM) or MK-2206 (0 nM, 100 nM, 250 nM, 1000 nM). After 24 hours of drug treatment, lysates were prepared and equal amounts of protein were load ed onto SDS-PAGE gels and blotted with the indicated antibodies.

    MK-2206 2HCl purchased from Selleck.

Purity & Quality Control

Choose Selective Akt Inhibitors

Biological Activity

Description MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2.
Features The first allosteric small molecule inhibitor of Akt to enter clinical development.
Targets
Akt1 [1]
(Cell-free assay)		 Akt2 [1]
(Cell-free assay)		 Akt3 [1]
(Cell-free assay)
8 nM 12 nM 65 nM
In vitro

MK-2206 is an allosteric inhibitor and is activated by the pleckstrin homology domain. MK-2206 inhibits auto-phosphorylation of both Akt T308 and S473. MK-2206 also prevents Akt-mediated phosphorylation of downstream signaling molecules, including TSC2, PRAS40 and ribosomal S6 proteins. [1] MK-2206 inhibits Ras wild-type (WT) cell lines (A431, HCC827, and NCI-H292) more potently when compared to Ras-mutant cell lines (NCI-H358, NCI-H23, NCI-H1299, and Calu-6). MK-2206 also shows synergistic responses in combination with cytotoxic agents such as erlotinib or lapatinib in lung NCI-H460 or ovarian A2780 tumor cells. [2] MK-2206 or siRNA-mediated Akt inhibition strongly activates autophagy in human glioma cells. However, eukaryotic elongation factor-2 (eEF-2) silencing suppresses MK-2206-induced-autophagy, with a promotion of apoptotic cell death. [3]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
NCI-H292 NFLVeG9EgXSxdH;4bYMhSXO|YYm= M4jk[FMh|ryP NHPsRpM4OiCq MnfoSG1UVw>? NF3uPJBKdmirYnn0bY9vKG:oIHPlcIwheHKxbHnm[ZJifGmxbh?= M2T0TVIxPTdzME[5
A431 M4\sc2tqdmG|ZTDBd5NigQ>? NIXwfmE2KM7:TR?= MXy1JIg> MWjEUXNQ NITBSXJUfXCycnXzd4V{KHSqZTDzbYdv[Wyrbnegc4YhSWu2IHHu[EBGemt? NYTCS4JNOjB3N{GwOlk>
HepG2 MkDvR5l1d3SxeHnjJGF{e2G7 Ml3CNVAh|ryP MXGyOEBp NXW2Z2N6TE2VTx?= MYnT[Y5{cXSrenXzJJJme2m|dHHueEBk\WyuczD0c{B1cGViY4n0c5RwgGmlIHXm[oVkfCCxZjDzc5Ji\mWwaXK= NGDDOHczOTJyNUmyOS=>
Sk-Hep1 NVztOnpYS3m2b4TvfIlkKEG|c3H5 NXnTfIFVOTBizszN NFH5NXYzPCCq NF7sZnpFVVOR NEL3[VVU\W6|aYTpfoV{KHKnc3nzeIFvfCClZXzsd{B1dyC2aHWgZ5l1d3SxeHnjJIVn\mWldDDv[kB{d3KjZnXubYI> MmjqNlEzODV7MkW=
OCUT1 cells harbored PIK3CA (H1047R+/+) NFrHZWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXEN{DPxE1? NETQbGY2KGR? NHvIbIdFVVOR MlLPTWM2OD1yLkG0JO69VQ>? NXOzWJZ2OjF{OEmyOlc>
K1 cells harbored PIK3CA (E542K+/+) NXm4fJBbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DGdVMh|ryP MkDqOUBl MXLEUXNQ NYjHPFhHUUN3ME2wMlUzKM7:TR?= MoLaNlEzQDl{Nke=
FTC133 cells harbored PTEN (allele deletion and R130+) NGfNc49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{O2dFMh|ryP Mn73OUBl M2HFSmROW09? MljlTWM2OD1yLkG4JO69VQ>? Mm\5NlEzQDl{Nke=
C643 cells harbored HRAS (G13R+/−) NWTiT2NbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7ZZYNROyEQvF2= M4nDV|Uh\A>? M3u5UmROW09? NXnoSXJ5UUN3ME2wMlI4KM7:TR?= M3OzOVIyOjh7Mk[3
Hth7 cells harbored NRAS (Q61R+/−) NGnkVGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TYclMh|ryP NIO5PYM2KGR? NXLjelBITE2VTx?= NEC3ZY1KSzVyPUSuOUDPxE1? MnnlNlEzQDl{Nke=
TPC1 cells harbored RET/PTC1 rearrangement M{XCNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17Ic|Mh|ryP MVy1JIQ> M1m1bGROW09? Mn60TWM2OD1yLkW5JO69VQ>? MXeyNVI5QTJ4Nx?=
Hth74 MkLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXqzJO69VQ>? NHj2eG42KGR? M3TUUGROW09? Mn\4TWM2OD1{LkG5JO69VQ>? M4TYbFIyOjh7Mk[3
KAT18 NIXUPYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjONXg{OyEQvF2= MlXCOUBl MmTBSG1UVw>? NGnLfI1KSzVyPUSuOlIh|ryP MVqyNVI5QTJ4Nx?=
SW1736 NE\KZY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXyxNFAh|ryP NYTwdJBKPSCm MVLEUXNQ MWHJR|UxRTR5LkW2JO69VQ>? M3fRclIyOjh7Mk[3
WRO NX31d4Z7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PCTVExODBizszN M2KxRVUh\A>? M3;Ve2ROW09? MVPJR|UxRjFyMECg{txO NV7GNIREOjF{OEmyOlc>
TAD2 NYnIcIZQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLiO2N3OTByMDFOwG0> M4m2XFUh\A>? M{XmRmROW09? NXX2UHJVUUN3ME6xNFAxKM7:TR?= NHHnO4kzOTJ6OUK2Oy=>
LN229 M4fn[GFxd3C2b4Ppd{BCe3OjeR?= NV\l[|JwOC53IN88US=> Mm[5OlAhcA>? M4WzVmROW09? NX:4RZZsSXWpbXXueJMh[XCxcITv[4VvcWNiZX\m[YN1eyCxZjDn[YZqfGmwaXK= NFjBW40zOjB3N{mxOC=>
T98G NVrDPY9sSXCxcITvd4l{KEG|c3H5 NYLBb|E6OC53IN88US=> MYm2NEBp M1LmbmROW09? NGHwVHhCfWevZX70d{BieG:ydH;n[Y5q[yCnZn\lZ5R{KG:oIHfl[ol1cW6rYh?= NU[3O5dQOjJyNUe5NVQ>
HC11 MnXpSpVv[3Srb36gRZN{[Xl? M4G2eFExKM7:TR?= Ml;sNlQhcA>? NGTvZVJFVVOR M3uzcWlvcGmkaYTzJO6zNWOjc3XpckBidmRiQVTSVEB{gW62aHXzbZM> NInyPVAzOjR{Nk[yNS=>
MOLT-4 NUjreWVXS3m2b4TvfIlkKEG|c3H5 MWCxNEDPxE1? M4nRelQ5KGh? MljWSG1UVw>? NULMbFdHUUN3ME2xMlfjiIoQvF2= M4\RWlIzPjF2MkSz
CEM-R M3TtSmN6fG:2b4jpZ{BCe3OjeR?= M{LIV|ExKM7:TR?= NIfjdXE1QCCq M{G1XGROW09? MVzJR|UxRTNwM,MAje69VQ>? NITuUpMzOjZzNEK0Ny=>
CEM-S MYLDfZRwfG:6aXOgRZN{[Xl? NFvxWHQyOCEQvF2= MY[0PEBp MYrEUXNQ NGXIdJFKSzVyPUWuNgKBkc7:TR?= MUOyNlYyPDJ2Mx?=
MOLT-4 NUjuPI5mTnWwY4Tpc44hSXO|YYm= MnjZNVAh|ryP NF\HNYszPCCq Ml;mSG1UVw>? Mn7nRoxw[2u|IHPlcIx{KGmwIITo[UBIOC:JMTDwbIF{\SCxZjD0bIUh[2WubDDjfYNt\Q>? M4LuOFIzPjF2MkSz
MOLT-4 M1nSO2Z2dmO2aX;uJGF{e2G7 MWK05qCK|ryP NYDIZXY3PCCq Mly2SG1UVw>? M1e3Wmlv[3KnYYPld{B1cGViYX3veY51KG:oIHPs[YF3\WRiTFOzRU9DNCCjIIflcIwu\XO2YXLsbZNp\WRiYYX0c5Bp[We7IH3hdotmeg>? MWWyNlYyPDJ2Mx?=
CEM-R NIXEW|lHfW6ldHnvckBCe3OjeR?= M{Hk[VTjiIoQvF2= M4W0VFQhcA>? NFPmUIlFVVOR MUfJcoNz\WG|ZYOgeIhmKGGvb4XueEBw\iClbHXheoVlKEyFNFGvRkwh[SC5ZXzsMYV{fGGkbHnzbIVlKGG3dH;wbIFogSCvYYLr[ZI> MVeyNlYyPDJ2Mx?=
CEM-S NEfLdHhHfW6ldHnvckBCe3OjeR?= NWK3VFRjPOLCid88US=> NH;ZT2c1KGh? MUXEUXNQ Mkn3TY5kemWjc3XzJJRp\SCjbX;1cpQhd2ZiY3zlZZZm\CCOQ{XBM2ItKGFid3XscE1me3SjYnzpd4hm\CCjdYTvdIhi\3libXHyb4Vz M4PyclIzPjF2MkSz
HepG2 cell MYjLbY5ie2ViQYPzZZk> MYOyNEDPxE1? M33kdVI1KGh? NFzPNphFVVOR NHHXbYxFd3ewcnXneYxifGW|IITo[UBxcG:|cHjvdplt[XSrb36gc4YhSUuW NFLzdGIzOzd7N{OxPS=>
HepG2 cell NX7aTG1IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LndVMxKM7:TR?= NXWyVZZiOjRiaB?= M{n5TGROW09? M1XJU2lvcGmkaYTzJINmdGxiZ4Lve5Rp NYDudoliOjN5OUezNVk>
HepG2 cell M4rlbGFxd3C2b4Ppd{BCe3OjeR?= Ml;TNlAh|ryP M{\aSVI1KGh? NXHifpdKTE2VTx?= NUPv[IdlUW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MlfLNlM4QTd|MUm=
GEO MoTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrMWIVrPTByIH7N NXTjWFJ7PzJiaB?= MVjEUXNQ NYjBV5BnUW6qaXLpeJMh[2WubDDndo94fGh? M1LnflI1PThzMkOx
CNE-1 MkC1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3T4cFExKM7:TR?= MUC5OkBp Mn7vSG1UVw>? MnSxTWM2OD1{Lkm2JO69VQ>? NX\MeFg3OjV|M{[5NlU>
CNE-2 NUL4N3VJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmj5NVAh|ryP MYW5OkBp NGnIeo5FVVOR M3TpTWlEPTB;ND61N{DPxE1? M{DDblI2OzN4OUK1
HONE-1 MnWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXuSHRJOTBizszN NIS2Zmc6PiCq NXvqTG1GTE2VTx?= MYHJR|UxRTNwM{eg{txO NFzQR4wzPTN|NkmyOS=>
SUNE-1 MonqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYexNEDPxE1? NX\4enpuQTZiaB?= M3HqeWROW09? NXjkVG1qUUN3ME2wMlUzKM7:TR?= MnLWNlU{OzZ7MkW=
CNE-2 M1GySmZ2dmO2aX;uJGF{e2G7 MUmxNEDPxE1? NIrmW5c1QCCq M{fhdGROW09? M3TEeGlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4SgZZQhTzF? NXj6dG5FOjV|M{[5NlU>
HONE-1 NYLWSotXTnWwY4Tpc44hSXO|YYm= MX:xNEDPxE1? M13uXFQ5KGh? MmXRSG1UVw>? Moq3TY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dDDheEBIOQ>? M3OzU|I2OzN4OUK1
NEC8 NHm4ZYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo[3TWM2OD1yLkC5OlUyKM7:TR?= MnHkV2FPT0WU
P12-ICHIKAWA NELCW3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXJc2NKSzVyPUCuNVE3OiEQvF2= MnflV2FPT0WU
MDA-MB-175-VII MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjCTWhtUUN3ME2wMlE{PzN6IN88US=> NFjVbohUSU6JRWK=
AsPC-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGS4N4lKSzVyPUCuNlIyOjJizszN MknRV2FPT0WU
T47D NFzmN2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTBwMkiyOUDPxE1? M3mzS3NCVkeHUh?=
HH NF3zS45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DIWGlEPTB;MD6zNFI5OyEQvF2= NYD5XIJyW0GQR1XS
MOLT-16 Mk\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HqSmlEPTB;MD6zNFMzKM7:TR?= NXzoVXREW0GQR1XS
ES5 Ml\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzzTWM2OD1yLkO0OFU2KM7:TR?= MkLuV2FPT0WU
RS4-11 M1;BXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DMNWlEPTB;MD6zOFYyKM7:TR?= NXjJSWVsW0GQR1XS
KARPAS-45 M3rvNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7OTIlQUUN3ME2wMlM4OzJzIN88US=> MnHzV2FPT0WU
NCI-H720 M1v3VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTBwM{e2O|kh|ryP NFvGSZVUSU6JRWK=
H9 NIXUUIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3r5UmlEPTB;MD6zPFg5OyEQvF2= MWjTRW5ITVJ?
EFM-19 MoHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\LTWM2OD1yLkS0NFEh|ryP M2fEVXNCVkeHUh?=
SBC-1 M1vJSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWO3RoNGUUN3ME2wMlQ1ODN3IN88US=> MWHTRW5ITVJ?
A4-Fuk NYXpSINFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn:0TWM2OD1yLkS2PFY5KM7:TR?= NHLrVZRUSU6JRWK=
NCI-H1563 MkDMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTBwNEixPFkh|ryP MnO5V2FPT0WU
HCC1419 NYDU[m5VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnkUYZKSzVyPUCuOFg5QTJizszN MnLuV2FPT0WU
H-EMC-SS M2C2SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEf3flVKSzVyPUCuOFk6OzlizszN MlfTV2FPT0WU
BHT-101 M4D1dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTBwNUK5OlEh|ryP M4n5T3NCVkeHUh?=
IGROV-1 M4rCSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTBwNUWyOFkh|ryP M1i5TXNCVkeHUh?=
HGC-27 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTBwNU[3PFMh|ryP M3P2R3NCVkeHUh?=
MDA-MB-361 MkTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTBwNUe3OlEh|ryP NELhdHhUSU6JRWK=
KE-37 NWnFSIVjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETDOIRKSzVyPUCuOVgzPiEQvF2= M3m3TXNCVkeHUh?=
HCC70 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\4dmlEPTB;MD61PVgzPyEQvF2= M3jlUXNCVkeHUh?=
LNCaP-Clone-FGC MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nxcWlEPTB;MD62NVA1QCEQvF2= M3vFXXNCVkeHUh?=
HAL-01 MknjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofjTWM2OD1yLk[yNVMh|ryP MY\TRW5ITVJ?
HT MknCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTBwNkOyN|kh|ryP NYTIXY9LW0GQR1XS
MDA-MB-415 NHi4WmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzrTYJKSzVyPUCuOlM3OjZizszN M1XLOHNCVkeHUh?=
NOS-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvMTWM2OD1yLk[zO|I{KM7:TR?= NFXKSIlUSU6JRWK=
DU-145 NE\vNolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDHXZE{UUN3ME2wMlY1PzR3IN88US=> MnT5V2FPT0WU
OCUB-M MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV34RoRSUUN3ME2wMlcxQTZ4IN88US=> NH\aOIRUSU6JRWK=
VA-ES-BJ NYjQUFFET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDzTWM2OD1yLkezNFI2KM7:TR?= MmPnV2FPT0WU
J-RT3-T3-5 M2DQTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XRe2lEPTB;MD63OFQxOyEQvF2= NVfaeY9iW0GQR1XS
MOLT-4 M{H3Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;uRVFOUUN3ME2wMlgxPTh{IN88US=> MoC2V2FPT0WU
NB7 NYDVUlF2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fhNWlEPTB;MD64NlQyOSEQvF2= M{XOfHNCVkeHUh?=
L-363 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTBwOEO0OFIh|ryP MknoV2FPT0WU
NKM-1 NHrhN29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXmSWJHUUN3ME2wMlg3OjV|IN88US=> Mn[2V2FPT0WU
HOP-92 NYi2N3R4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2j1WmlEPTB;MD64O|IzOyEQvF2= MYfTRW5ITVJ?
OAW-42 M1vtZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTBwOEi3NkDPxE1? MnrBV2FPT0WU
HuO9 NIfnUlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{e4UGlEPTB;MD65Nlc2OSEQvF2= NWXIOmptW0GQR1XS
MFE-280 NYm1[WlpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\4UWlEPTB;MD65OlQ3PSEQvF2= NXvqO2l6W0GQR1XS
EM-2 MkflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTKVlJKSzVyPUCuPVc6OzlizszN NWfX[m1lW0GQR1XS
NCI-H520 NETSNnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7uTWM2OD1yLkm4OVkzKM7:TR?= MUnTRW5ITVJ?
LB2241-RCC NWPpR4NmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIGydIhKSzVyPUCuPVk4OzRizszN NEDicYdUSU6JRWK=
SK-NEP-1 NHrPRXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofSTWM2OD1zLkG0OFg2KM7:TR?= M4XuO3NCVkeHUh?=
LXF-289 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTLe2tKSzVyPUGuNVcyPTZizszN NYKxNVlbW0GQR1XS
EPLC-272H NYKwXoFZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XqcWlEPTB;MT6xO|I2PiEQvF2= NV;3T2hDW0GQR1XS
COLO-684 MnzuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mly3TWM2OD1zLkKzO|I2KM7:TR?= NIr4NmRUSU6JRWK=
ES1 NF\2NXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFftUIdKSzVyPUGuNlQxPjVizszN MoLvV2FPT0WU
DOHH-2 NVLqd5I2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jLO2lEPTB;MT6yPFIxOyEQvF2= NX;KZ5B[W0GQR1XS
CTB-1 NHz0[nJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULLUY1rUUN3ME2xMlI5QTlizszN NY\YcoxGW0GQR1XS
G-401 Mmr1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTFwMkm3PVUh|ryP NGDFcolUSU6JRWK=
LoVo MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnpVVdKSzVyPUGuN|I2OzRizszN M1nLO3NCVkeHUh?=
Ramos-2G6-4C10 NXHGRXlnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnJTWM2OD1zLkOzO|AyKM7:TR?= Mnr6V2FPT0WU
MFM-223 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\IXWlEPTB;MT6zOFQ3OSEQvF2= NIG2cppUSU6JRWK=
PA-1 NEWzeHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjyRm5kUUN3ME2xMlM2OjZ3IN88US=> M1GwNXNCVkeHUh?=
697 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXQRYlnUUN3ME2xMlM4PjF4IN88US=> M33jS3NCVkeHUh?=
QIMR-WIL Mom4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnsPY9OUUN3ME2xMlQ6OTF4IN88US=> MnLMV2FPT0WU
HOS MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\qTWM2OD1zLkS5OVU5KM7:TR?= MULTRW5ITVJ?
DMS-273 MlzyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7YOZRMUUN3ME2xMlUyQTV7IN88US=> NXGzSldKW0GQR1XS
ME-180 NUWwS3hVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTFwNU[4PVEh|ryP MW\TRW5ITVJ?
HCC2218 NX;6ZWNpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITidJBKSzVyPUGuOlgzOjVizszN NIryWYtUSU6JRWK=
CAL-54 NX22SI45T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoK4TWM2OD1zLkexNlQzKM7:TR?= MlLyV2FPT0WU
OMC-1 M2\Te2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LZXmlEPTB;MT63OFY4PyEQvF2= MWLTRW5ITVJ?
COR-L105 Mli1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvsTWM2OD1zLke5O|M4KM7:TR?= MmrCV2FPT0WU
BV-173 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M323cGlEPTB;MT64NVA4PCEQvF2= NYTFS2dJW0GQR1XS
RKO MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTFwOEexNFEh|ryP NX7PSoJjW0GQR1XS
SNU-387 NHW5U2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\RW444UUN3ME2xMlg5PDB4IN88US=> Mo\xV2FPT0WU
SW1088 NWLmU4FUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DFSGlEPTB;MT65OFYxPiEQvF2= MmHWV2FPT0WU
Hs-578-T NGq0WWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTJwMUG0N|Mh|ryP M2CzdXNCVkeHUh?=
OC-314 MkXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7NRm1KSzVyPUKuNVUxQDZizszN M2PnNHNCVkeHUh?=
RMG-I NWPucGRWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDSOXNTUUN3ME2yMlE3Ozl6IN88US=> M{\EWnNCVkeHUh?=
NCI-H1395 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17RNWlEPTB;Mj6xPFA6OSEQvF2= MlrOV2FPT0WU
GAMG NF25Zm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\KUFdpUUN3ME2yMlI{QDR3IN88US=> NIHkZ2VUSU6JRWK=
LB1047-RCC NHr0UFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXaTWM2OD1{LkK0N|E4KM7:TR?= M{XLUXNCVkeHUh?=
MN-60 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7SUIF7UUN3ME2yMlI6QTJ|IN88US=> M4\C[XNCVkeHUh?=
OAW-28 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjZNYJKSzVyPUKuNlk6PTFizszN MojKV2FPT0WU
NCI-H2228 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3VO4pKSzVyPUKuN|E2PTJizszN NXr0XmRjW0GQR1XS
ABC-1 M4j6S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFv0XFJKSzVyPUKuN|MzPTNizszN Moj3V2FPT0WU
LS-513 NGrVVo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTJwM{O0PFQh|ryP NHfkW41USU6JRWK=
KS-1 M4n2T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHX3e21KSzVyPUKuN|gyQTFizszN NH3HfpRUSU6JRWK=
NB69 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\SboRKSzVyPUKuN|g6QDNizszN MYDTRW5ITVJ?
VM-CUB-1 NYf4[XFHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorxTWM2OD1{LkO5NFg{KM7:TR?= MYLTRW5ITVJ?
D-423MG NU\TXZBxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTJwNEGwOFQh|ryP NIfxXJVUSU6JRWK=
EW-18 NIDlR4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{izV2lEPTB;Mj60NVk{QSEQvF2= NGrZdoJUSU6JRWK=
YH-13 NV7zUY46T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGOwPINKSzVyPUKuOFYyPTNizszN MnP4V2FPT0WU
T-24 M1fkTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTJwNEe4PFEh|ryP NYDQSotEW0GQR1XS
ES8 MlTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHMXYFKSzVyPUKuOFkzQDdizszN NFj5bGRUSU6JRWK=
ES3 Mo\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\xNGtKSzVyPUKuOFk4PTlizszN NYr1cW83W0GQR1XS
RXF393 NFjmVlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTJwNkC0PFch|ryP NWWzVmpmW0GQR1XS
RPMI-8226 MnLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXjbG0{UUN3ME2yMlYzQTV|IN88US=> M4T0PHNCVkeHUh?=
AGS NIPWN2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYD6d5R6UUN3ME2yMlczOTN5IN88US=> Mo\WV2FPT0WU
HCC1395 NFvqS4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\LV2RKSzVyPUKuO|UyQDdizszN MXzTRW5ITVJ?
MV-4-11 MmezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfOe49WUUN3ME2yMlc2OjZ4IN88US=> M4LqUHNCVkeHUh?=
A204 NUTEdIV4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVToN3NuUUN3ME2yMlg{QDd{IN88US=> MmrmV2FPT0WU
MCF7 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTJwOE[xNVch|ryP MlzsV2FPT0WU
SNU-423 M371XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYO1N5JNUUN3ME2yMlg6OjR{IN88US=> NG\vTJpUSU6JRWK=
NCI-H1048 Mo\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIm1XIZKSzVyPUKuPVY5PjVizszN MXzTRW5ITVJ?
GR-ST NX76TGZuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1GwN2lEPTB;Mz6wOFYyOSEQvF2= MXjTRW5ITVJ?
EoL-1- NILpO29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XlXGlEPTB;Mz6wO|A2QCEQvF2= NWGxOHpMW0GQR1XS
HuH-7 NEnjSnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPjTWM2OD1|LkC5OFY1KM7:TR?= MkXRV2FPT0WU
OS-RC-2 NUX2VpJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTNwMUGxPUDPxE1? MlzlV2FPT0WU
EW-3 M2fWNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLVe4lKSzVyPUOuNVk2OjlizszN NVnFOlY4W0GQR1XS
NCI-H747 M4W2Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrtVGU3UUN3ME2zMlIxPjl2IN88US=> MXnTRW5ITVJ?
EW-16 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XSTmlEPTB;Mz6yNVg4QSEQvF2= M2CyXnNCVkeHUh?=
DOK Mmm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHxPVhKSzVyPUOuNlI5PTlizszN Mon3V2FPT0WU
HCC2157 NUH5flZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HxNWlEPTB;Mz6zPFE4QSEQvF2= NVzCXo1RW0GQR1XS
OVCAR-3 NVL6cIFRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmroTWM2OD1|LkSwO|g3KM7:TR?= MWHTRW5ITVJ?
NCI-H1623 M3u4VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYe2[WpZUUN3ME2zMlQyOjJ2IN88US=> Mn;SV2FPT0WU
H4 Mnr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTNwNEW2NlYh|ryP MYLTRW5ITVJ?
SW1710 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HsPWlEPTB;Mz60OlY4QCEQvF2= M3HLSHNCVkeHUh?=
RT-112 M33SSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nOTGlEPTB;Mz61NlM5QCEQvF2= NGe3fVhUSU6JRWK=
DMS-114 M33uRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zjbGlEPTB;Mz62NlI4QCEQvF2= MXPTRW5ITVJ?
AN3-CA MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTNwNkK0OVYh|ryP NITJeGhUSU6JRWK=
KNS-62 NVXZRZJRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLYNlROUUN3ME2zMlY{OzN6IN88US=> MoDHV2FPT0WU
SJRH30 NH;NXVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3v6SmlEPTB;Mz62PVEzOiEQvF2= MUXTRW5ITVJ?
G-402 MkTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fVemlEPTB;Mz63NFcyOSEQvF2= M3jlVnNCVkeHUh?=
MHH-PREB-1 M37WUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHUXGtxUUN3ME2zMlczODN6IN88US=> NFjIXIFUSU6JRWK=
P30-OHK MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGroU3RKSzVyPUOuPFA6PzZizszN MXTTRW5ITVJ?
RVH-421 M3HMSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\zcGlEPTB;Mz64NVc5QCEQvF2= NIfNcopUSU6JRWK=
LU-134-A MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTHbHFVUUN3ME2zMlg5PDJ6IN88US=> MYPTRW5ITVJ?
ECC10 MoPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTNwOUO2NlIh|ryP Ml\iV2FPT0WU
TGW M2Gzbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXT0elhnUUN3ME20MlAzOzB3IN88US=> Mnu0V2FPT0WU
MLMA NYLnbYZuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTRwMEK5OlYh|ryP NHntdGFUSU6JRWK=
SCC-25 M1vnOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LZWGlEPTB;ND6wOlU3PiEQvF2= NIKwW3ZUSU6JRWK=
TYK-nu Mnn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzRTWM2OD12LkC5OVM1KM7:TR?= NVv1OWpIW0GQR1XS
LAMA-84 NEDRT|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7WZY1KSzVyPUSuNVQyQTFizszN M4HkWHNCVkeHUh?=
Calu-3 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mni0TWM2OD12LkK0OFE3KM7:TR?= MoDEV2FPT0WU
NCI-H460 NIDXbJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;Sc2lEPTB;ND6yOlQ1OyEQvF2= MWXTRW5ITVJ?
EGI-1 NHrsb4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTRwM{e3O|gh|ryP NXLUZ41pW0GQR1XS
NCI-H292 NVm1WZFzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVq5XnZYUUN3ME20MlM5OTR4IN88US=> M2r5fXNCVkeHUh?=
HCE-T M1TKbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mly0TWM2OD12LkSxOVc6KM7:TR?= NWriToUzW0GQR1XS
EW-11 NFHCcWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvETWM2OD12LkSxPFM5KM7:TR?= NWjhdWc{W0GQR1XS
ATN-1 M{\6ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3n0cmlEPTB;ND60OFMxPCEQvF2= MlexV2FPT0WU
NB5 NX7CUGhlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYD5RXlRUUN3ME20MlU{Pjl5IN88US=> NHP4eZRUSU6JRWK=
KLE NV3O[m9jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\5TWgyUUN3ME20MlcxOTl6IN88US=> MX\TRW5ITVJ?
CAL-39 Mk[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDpb2pkUUN3ME20MlczOTR4IN88US=> NFnCTYJUSU6JRWK=
TI-73 NX[ySmlYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\QTWM2OD12LkiwOlA6KM7:TR?= NHjoPW5USU6JRWK=
HO-1-N-1 NEHoNW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHKV2RKSzVyPUSuPVQzKM7:TR?= NFXEV5pUSU6JRWK=
786-0 Ml3yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\2[WlEPTB;ND65OFY4OyEQvF2= MWnTRW5ITVJ?
SK-N-DZ MlnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV[0U2k6UUN3ME20Mlk3OTR{IN88US=> MWTTRW5ITVJ?
NCI-H446 NYfkdYVYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2r5ZmlEPTB;NT6yNFAxQSEQvF2= NF;RVFJUSU6JRWK=
ETK-1 M1y2bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHflNXZKSzVyPUWuNlEyPjVizszN MmLQV2FPT0WU
BT-20 MmfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XyPWlEPTB;NT6yNVM2OyEQvF2= NFLV[lZUSU6JRWK=
MEL-HO NEPMb|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnHNpN4UUN3ME21MlM4OzN4IN88US=> MmnSV2FPT0WU
CAL-27 NHzwRVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LvdmlEPTB;NT60OlM{QSEQvF2= MXXTRW5ITVJ?
SW872 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\hTWM2OD13LkW5OFI5KM7:TR?= M1TPV3NCVkeHUh?=
RPMI-2650 NFrse5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUn3bXNPUUN3ME21MlY3OTl7IN88US=> MWPTRW5ITVJ?
PFSK-1 Mo\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjFTW9KSzVyPUWuO|I4OzJizszN NFLlW5dUSU6JRWK=
SF295 NUnl[Yw6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;zTWM2OD13LkiwOlM{KM7:TR?= MkX0V2FPT0WU
Becker M3X6RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTVwOE[0O|Ih|ryP NXrMNWFVW0GQR1XS
Saos-2 NX\jfFNFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrpTWM2OD13Lki2OVMh|ryP M2HXd3NCVkeHUh?=
SK-OV-3 NYfIfGJCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFq3c2VKSzVyPUWuPVk5OTZizszN NWjke3lTW0GQR1XS
VMRC-RCZ NEDSOnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzvTWM2OD14LkC4O|c{KM7:TR?= NFPkbWNUSU6JRWK=
EW-22 NFnRVmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzFOXNKSzVyPU[uNVk3PDlizszN NWmyRW9rW0GQR1XS
BT-474 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTuS2d6UUN3ME22MlI{OyEQvF2= MmO3V2FPT0WU
BFTC-909 NEjm[FJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTZwM{CzOFUh|ryP MlrqV2FPT0WU
NB12 NG\6e5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfC[29KSzVyPU[uN|kxPzFizszN NGTHWppUSU6JRWK=
D-263MG NXvve29ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTaOmxKSzVyPU[uOFUyPjlizszN MoC5V2FPT0WU
SNB75 NVjuO3ZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnK2TWM2OD14Lk[wNVQ{KM7:TR?= MYjTRW5ITVJ?
A704 MmXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHvWZFKSzVyPU[uOlMxPiEQvF2= NEjuelVUSU6JRWK=
NCI-H1693 NYWxZmhJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTZwNkO2NFQh|ryP NEPa[IlUSU6JRWK=
LN-405 NYG1NphkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoX6TWM2OD14Lke5OlczKM7:TR?= NY\jSGRkW0GQR1XS
CHL-1 M33tdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TSc2lEPTB;Nj64NFA4QSEQvF2= MULTRW5ITVJ?
A498 MlHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTZwOEG5OlEh|ryP NXvabY1CW0GQR1XS
TE-12 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLzb5lnUUN3ME22Mlg{QDF5IN88US=> NIn0bWdUSU6JRWK=
TE-6 NXHHT5poT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXDcGtUUUN3ME22Mlk{ODN6IN88US=> M{nhOXNCVkeHUh?=
AU565 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnPTWM2OD14Lkm2PVU4KM7:TR?= NFzyW49USU6JRWK=
RD NFr2bYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTZwOUiyPFQh|ryP MXPTRW5ITVJ?
SW1463 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIKxUWdKSzVyPUeuNVEyPjhizszN M2DrXXNCVkeHUh?=
LU-99A NHPSWZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXqbFJKSzVyPUeuNVQ{OjJizszN MnTHV2FPT0WU
NCI-H28 NX;xOXhMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zCTWlEPTB;Nz6yPVI1KM7:TR?= NEXYR2dUSU6JRWK=
MC-IXC NVvPcmNnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\1TpNKSzVyPUeuOFg2PzZizszN M1TGWXNCVkeHUh?=
GP5d M2DJTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TKNmlEPTB;Nz60PFc3PCEQvF2= MUjTRW5ITVJ?
GB-1 NFnDS4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXQTWM2OD15LkW0PFA1KM7:TR?= NX\QRY9kW0GQR1XS
CAL-33 NF\6TXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nmcmlEPTB;Nz62OlI{OyEQvF2= MVzTRW5ITVJ?
MSTO-211H MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTdwNkezN|Yh|ryP NUHyU41sW0GQR1XS
TE-5 NWDLcm1ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFG1c2FKSzVyPUeuO|k{OzRizszN M3\lNHNCVkeHUh?=
D-566MG MmLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13rfmlEPTB;OD6wOFQzQSEQvF2= MonXV2FPT0WU
JVM-3 MoXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPZXXY3UUN3ME24MlE2OjZ6IN88US=> MV7TRW5ITVJ?
T98G Ml;IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVOz[3NEUUN3ME24MlE5ODZ5IN88US=> NX;RVodrW0GQR1XS
HCC1954 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjRN3FKSzVyPUiuOFUyODRizszN M1;0Z3NCVkeHUh?=
SF126 NXm5TGFWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvXTWM2OD16LkS1PVM3KM7:TR?= M2DzNHNCVkeHUh?=
LB996-RCC NF3kc41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXOUY5KSzVyPUiuOVMzPTdizszN MXfTRW5ITVJ?
SKG-IIIa MmnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLBOpdKSzVyPUiuOlMxPjlizszN NUDCc2hDW0GQR1XS
NCI-SNU-1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRThwNkS2OFMh|ryP NYrwfWJkW0GQR1XS
LB771-HNC NU\hWppiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;2TWM2OD16Lk[0Olk3KM7:TR?= M1nUTXNCVkeHUh?=
SCC-4 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILwcJVKSzVyPUiuOlgzOTlizszN NXPKS3RQW0GQR1XS
CAMA-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjDSm1SUUN3ME24Mlc4OTR4IN88US=> MVjTRW5ITVJ?
D-502MG MoLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFWzO2dKSzVyPUiuO|g3OjlizszN MXPTRW5ITVJ?
ESS-1 NYr4VIN1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfIVnZKSzVyPUiuPFg4ODRizszN NFTsd3BUSU6JRWK=
HEC-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPZTWM2OD16Lki5PFY3KM7:TR?= M{\x[XNCVkeHUh?=
NB10 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vLT2lEPTB;OT6wNlIzPCEQvF2= MWHTRW5ITVJ?
8505C MkTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXxTWM2OD17LkC0NlMzKM7:TR?= NILIcJZUSU6JRWK=
EFO-27 M3OzOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTlwMU[0NVIh|ryP M2OxWHNCVkeHUh?=
HN MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTlwMU[2Nlgh|ryP MoTXV2FPT0WU
DSH1 NFf3NW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTlwMkC4O{DPxE1? M4PmZnNCVkeHUh?=
NBsusSR Mn:0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUX2XFhyUUN3ME25MlI4PDB{IN88US=> NU\PPWpvW0GQR1XS
LS-123 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTlwM{G3OlEh|ryP M1PjT3NCVkeHUh?=
SHP-77 NE[2XmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHGSoNKSzVyPUmuN|k6OzVizszN M3Pa[3NCVkeHUh?=
ACN NV7XXodST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTlwNUOyO|ch|ryP MX\TRW5ITVJ?
U251 MljlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTlwNkW1OFQh|ryP NGnnTo9USU6JRWK=
A431 M2XqVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPrVnJKSzVyPUmuPFAzOzhizszN NW\uOHhHW0GQR1XS
5637 NX7vO2I2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\BdGlEPTB;OT64OFk5PCEQvF2= MV3TRW5ITVJ?
MDA-MB-157 MoLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnLNlI1UUN3ME25MlkzQDd6IN88US=> NVrTcWtSW0GQR1XS
A101D NVn5dGJZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrYTWM2OD17Lkm5PVc1KM7:TR?= NUPNWZE6W0GQR1XS
YKG-1 NWfqXWdiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DjdmlEPTB;MUCuNlAxPiEQvF2= MkfmV2FPT0WU
LAN-6 NYTWcGNyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTFyLkKxOlQh|ryP M2PFenNCVkeHUh?=
OVCAR-5 NYTVVHNvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDwN2ZKSzVyPUGwMlI1OzNizszN M1\6VXNCVkeHUh?=
A549 MnfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\nTWM2OD1zMD6zPVc{KM7:TR?= MmSyV2FPT0WU
no-11 MlTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nqT2lEPTB;MUCuOFM2OyEQvF2= M2TkWXNCVkeHUh?=
SF539 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHtOllyUUN3ME2xNE46ODRzIN88US=> MVLTRW5ITVJ?
A388 M2TwTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTFzLkO4PVch|ryP MmXiV2FPT0WU
DEL NVrYSGRJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DzSGlEPTB;MUGuOFI1KM7:TR?= M2G0bXNCVkeHUh?=
SW954 Mn\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTkPVNKSzVyPUGxMlQ3PjhizszN MXrTRW5ITVJ?
TK10 NYG4N5BVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTFzLkWyO|Eh|ryP NEPzeGFUSU6JRWK=
SW756 MkTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjJUnVjUUN3ME2xNU42Ojl2IN88US=> MkTJV2FPT0WU
PC-3 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvjTWM2OD1zMT61O|Y1KM7:TR?= M{HCWXNCVkeHUh?=
ONS-76 M4fYbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7DXok5UUN3ME2xNU43OzZizszN M{TUeXNCVkeHUh?=
A427 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEX3c3dKSzVyPUGxMlcxQTNizszN M{DPPXNCVkeHUh?=
MEG-01 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV73coR3UUN3ME2xNU44PTB7IN88US=> MVjTRW5ITVJ?
BB30-HNC NFXafpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\mTWM2OD1zMT63PVgzKM7:TR?= MYnTRW5ITVJ?
NCI-H1299 Ml[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M333NWlEPTB;MUGuPFA6OyEQvF2= Moe0V2FPT0WU
GCT NVnufmRsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M130bGlEPTB;MUGuPFIzQCEQvF2= NXTtbnpGW0GQR1XS
D-247MG NI\DNHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknKTWM2OD1zMT65OlY{KM7:TR?= NUTlfoFpW0GQR1XS
CFPAC-1 M3nsd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LJSmlEPTB;MUGuPVc5OiEQvF2= NVnaVlVzW0GQR1XS
EKVX NHTkNIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTF{LkCzNVMh|ryP MXfTRW5ITVJ?
CAL-51 Ml7rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTF{LkC3NVYh|ryP MVTTRW5ITVJ?
BB49-HNC NXTFPGJCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3[4PGlEPTB;MUKuNVE4PyEQvF2= NH34e2RUSU6JRWK=
RPMI-7951 MkP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1f0N2lEPTB;MUKuNVg2PCEQvF2= MknLV2FPT0WU
RH-1 M4X1O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XtRmlEPTB;MUKuNlE5PCEQvF2= M{L6V3NCVkeHUh?=
BCPAP NXPYUXRyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUeycJBFUUN3ME2xNk41PzR7IN88US=> NIniOVNUSU6JRWK=
GCIY NGH5VZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zxO2lEPTB;MUKuOVIxQSEQvF2= MlTpV2FPT0WU
KNS-81-FD MmjUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWD1WWJWUUN3ME2xNk42QDZ7IN88US=> NXHSZ2FxW0GQR1XS
KYSE-140 NHnHTJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTF{Lki1PVUh|ryP NX\WUHdUW0GQR1XS
Ca-Ski NXXqOXdpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTF{LkmwOFEh|ryP NH[4[ppUSU6JRWK=
TGBC1TKB NUPZZVhiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\qOXZUUUN3ME2xNk46OTF3IN88US=> MnXaV2FPT0WU
HCC1187 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rFV2lEPTB;MUOuNVkyOiEQvF2= MkL5V2FPT0WU
SJSA-1 M3PZTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPSN4lKSzVyPUGzMlI{OjdizszN MYPTRW5ITVJ?
CTV-1 M4TySWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGP0WFlKSzVyPUGzMlM1PSEQvF2= MVXTRW5ITVJ?
WM-115 M1XP[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI[3bVVKSzVyPUGzMlY1QDNizszN MVXTRW5ITVJ?
CHP-212 M4nzWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlruTWM2OD1zMz65O|M6KM7:TR?= MUDTRW5ITVJ?
SCC-15 M2nJNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLSOJJPUUN3ME2xN{46Pzd3IN88US=> NVy1d3dFW0GQR1XS
BPH-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTF2LkG2OlQh|ryP NWf5RnBHW0GQR1XS
SW780 MkDXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPBTWM2OD1zND61NFI2KM7:TR?= MV;TRW5ITVJ?
NCI-H2291 NIjBNlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTF2LkW4O|gh|ryP MWnTRW5ITVJ?
JEG-3 NIrnT|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWeyfI9KUUN3ME2xOE43OzJ4IN88US=> M12zOnNCVkeHUh?=
CAL-120 M{Xwemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjncppKSzVyPUG0MlcxOjdizszN MXHTRW5ITVJ?
NCI-H23 M3fsWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PDd2lEPTB;MUSuO|k6PyEQvF2= NFjyOYhUSU6JRWK=
MS-1 NELIW2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnyTWM2OD1zND65OlEyKM7:TR?= NY\URmNwW0GQR1XS
PC-14 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzqUIxTUUN3ME2xOE46PjV2IN88US=> NUfK[XNvW0GQR1XS
D-283MED NHXlOo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3oTWM2OD1zNT6wNVEyKM7:TR?= NFnte|hUSU6JRWK=
OE19 NGG0V45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfLRWdKSzVyPUG1MlE2PDFizszN M4jtVnNCVkeHUh?=
CAS-1 M2ezeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7ofmQ{UUN3ME2xOU41OTh2IN88US=> NFL4TWtUSU6JRWK=
NCI-H727 NEDtU5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTF3LkSyNlEh|ryP MoDSV2FPT0WU
SiHa MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7DVWVKSzVyPUG1Mlc2QTRizszN NWHQPVl3W0GQR1XS
BFTC-905 M{SxSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfv[nRKSzVyPUG1Mlc3QTRizszN MV3TRW5ITVJ?
MDA-MB-453 Mk[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\obngyUUN3ME2xOk4yPjR{IN88US=> NUDFRW4yW0GQR1XS
HuP-T3 M1vJfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDqfIVKSzVyPUG2MlY{PzNizszN NGP3PVFUSU6JRWK=
SK-LU-1 NYfqN|VxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTF4Lk[5OVYh|ryP Mn\HV2FPT0WU
Detroit562 M1T0VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTF4LkezNVgh|ryP NWTVe3NKW0GQR1XS
HCC1569 MnjjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmf4TWM2OD1zNj64N|M4KM7:TR?= MXnTRW5ITVJ?
SK-MES-1 NU\iT|k6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYThVo5{UUN3ME2xOk45PDF7IN88US=> NGW3UIlUSU6JRWK=
BB65-RCC MlyyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M370PWlEPTB;MUeuNFQ4QSEQvF2= NXfXcJFFW0GQR1XS
LOXIMVI M1nOO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\6TWM2OD1zNz6wO|A4KM7:TR?= MYjTRW5ITVJ?
SW1783 NV3FR211T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHkcWhqUUN3ME2xO{4yOjhizszN NYCzb5B[W0GQR1XS
NH-12 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37OZ2lEPTB;MUeuN|MxOyEQvF2= MYrTRW5ITVJ?
UACC-257 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnmWXp6UUN3ME2xO{42PTF{IN88US=> NX\kSHQzW0GQR1XS
KOSC-2 NYjEUHNvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{i3UmlEPTB;MUeuOlc2PyEQvF2= Mn\DV2FPT0WU
KG-1 M4fnVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rXXWlEPTB;MUeuOlk{PyEQvF2= NXS4dY5IW0GQR1XS
M059J NGH2Z4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml36TWM2OD1zNz63NFMh|ryP NXnNR|dtW0GQR1XS
MHH-NB-11 NWrZVGF7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XIVGlEPTB;MUeuPVY4OyEQvF2= M3vkW3NCVkeHUh?=
EW-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rKcWlEPTB;MUiuNVM5OiEQvF2= MoXWV2FPT0WU
CAL-85-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknwTWM2OD1zOD6yN|U4KM7:TR?= NX7BTFZsW0GQR1XS
639-V MkPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfOZWpKSzVyPUG4MlM{PTRizszN MWfTRW5ITVJ?
C32 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTF6LkS3Nlch|ryP MoXmV2FPT0WU
KM-H2 Moj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTF6LkWyN|Ih|ryP MVnTRW5ITVJ?
A253 MlPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fNeWlEPTB;MUiuO|I5PiEQvF2= M4HPd3NCVkeHUh?=
NCI-N87 Mk\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnBTWM2OD1zOD65NFA5KM7:TR?= MmjBV2FPT0WU
8-MG-BA MmnFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nkc2lEPTB;MUmuNFY1PiEQvF2= NXrEOYVzW0GQR1XS
GI-ME-N MmfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTF7LkG1OFYh|ryP MUPTRW5ITVJ?
8305C MlPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY[xd|JlUUN3ME2xPU4zOjh4IN88US=> MonQV2FPT0WU
TE-8 M4TGRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;T[2RKSzVyPUG5MlMxOjRizszN MorCV2FPT0WU
KYSE-270 NHfUW3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTJyLkCyNVch|ryP NGrPTIxUSU6JRWK=
HL-60 M{LvWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTJyLkC5OFEh|ryP NXHS[IZYW0GQR1XS
Mo-T M3nSbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTJyLkG2OlUh|ryP NWrZbWxtW0GQR1XS
NCI-H1355 M2\Ve2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHW3NmFKSzVyPUKwMlM{PzRizszN NX7aU4k3W0GQR1XS
HT-1080 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGX2d|VKSzVyPUKwMlU1QTdizszN M3XyWnNCVkeHUh?=
MIA-PaCa-2 NVLPeW9WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTJyLk[4PFMh|ryP M2DHWHNCVkeHUh?=
NCI-H441 NITh[|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\EO2VKSzVyPUKwMlc{PzlizszN NH3xWHRUSU6JRWK=
LCLC-97TM1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTJyLkixN|Qh|ryP MYrTRW5ITVJ?
HT-3 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTJzLkW2N|Eh|ryP NH\vRm1USU6JRWK=
22RV1 Mn\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfvd5JKSzVyPUKxMlU3QDVizszN M{XZSHNCVkeHUh?=
LK-2 M3fLRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHYTWM2OD1{MT61PVU{KM7:TR?= M135RXNCVkeHUh?=
CW-2 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW[wemVmUUN3ME2yNU43ODZ7IN88US=> MkLCV2FPT0WU
KYSE-510 NIXwbZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDMRodkUUN3ME2yNU43ODl3IN88US=> NWL5Om92W0GQR1XS
CGTH-W-1 NVX4OW5xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;4NXlKSzVyPUKxMlcyPjZizszN M1j3NnNCVkeHUh?=
NCI-H661 NVuxW5lQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHCVlV5UUN3ME2yNk4xOzRizszN MWrTRW5ITVJ?
KU-19-19 M3\HcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LEU2lEPTB;MkKuNVY6PyEQvF2= MXvTRW5ITVJ?
NCI-H2122 NX:wd4lxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjnTWM2OD1{Mj6yOFMzKM7:TR?= MlrOV2FPT0WU
NCI-H526 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPwNWFDUUN3ME2yNk4{QDl3IN88US=> NWrUc40yW0GQR1XS
NCI-H1650 M2ntVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\yZWtIUUN3ME2yNk44PjRizszN MYTTRW5ITVJ?
AM-38 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTJ{Lki2PFkh|ryP MlTKV2FPT0WU
NCI-H2405 M{GzOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzxRohKSzVyPUKzMlI2OzNizszN NYi3W2U2W0GQR1XS
M14 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2i5WmlEPTB;MkOuOFA5QCEQvF2= MnXDV2FPT0WU
ES4 M4nwN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDrboZKSzVyPUKzMlQzOzJizszN NEi3WZJUSU6JRWK=
DJM-1 MlK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfqVnBKSzVyPUKzMlUzOzRizszN NE\rd41USU6JRWK=
S-117 M1;C[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvaU|dKSzVyPUKzMlc3PTFizszN Ml;mV2FPT0WU
MZ2-MEL NIKxUHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvZcFhKSzVyPUKzMlc4PTlizszN MWjTRW5ITVJ?
SK-MEL-2 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDZVHBxUUN3ME2yN{45OTN|IN88US=> NFjuZWJUSU6JRWK=
HCC1806 NUnRdY51T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXK1THRiUUN3ME2yN{45PzB7IN88US=> M1jhfnNCVkeHUh?=
NMC-G1 MmPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M170T2lEPTB;MkSuNlIzPiEQvF2= MXfTRW5ITVJ?
DK-MG MkTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\uc3EyUUN3ME2yOE4zQTRizszN MoHxV2FPT0WU
SK-N-FI M3fMV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWL6fopRUUN3ME2yOE4{OzB{IN88US=> NI\XTJpUSU6JRWK=
KINGS-1 MojRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTJ2LkS4O|Qh|ryP M1yx[HNCVkeHUh?=
HCC2998 NVPaUIRLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTJ2LkS4PFUh|ryP MlvJV2FPT0WU
ALL-PO NWT5eotST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFe2NJVKSzVyPUK0MlYyQSEQvF2= NIixTIZUSU6JRWK=
MPP-89 NFrWcmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTJ3LkC0OVgh|ryP MYXTRW5ITVJ?
NCI-H2342 MkDLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13TZWlEPTB;MkWuNVk2OyEQvF2= MW\TRW5ITVJ?
TE-1 M1f2Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTJ3LkO1OlMh|ryP NY\EeIFvW0GQR1XS
RH-18 NFLxfVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHXeXVKSzVyPUK1MlU6OThizszN MWPTRW5ITVJ?
HT-1376 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3v2NmlEPTB;MkWuOlQ3PSEQvF2= MkfkV2FPT0WU
U-2-OS M2TlW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnDRpc4UUN3ME2yOU43QDh6IN88US=> MnLpV2FPT0WU
BT-549 NV7JS2czT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTJ3LkmwNVEh|ryP NFvpZnZUSU6JRWK=
NCI-H1755 Mn\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrIOVFKSzVyPUK1Mlk6PDVizszN MU\TRW5ITVJ?
EW-13 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1W4SmlEPTB;Mk[uNFI4PCEQvF2= MXrTRW5ITVJ?
NB13 M3LhUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTJ4LkC5OFkh|ryP MmfVV2FPT0WU
NUGC-3 NUTXSpJPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTJ4LkKxNFMh|ryP NGXqb5hUSU6JRWK=
GMS-10 MmPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnUZnpOUUN3ME2yOk4zOzV|IN88US=> MoDrV2FPT0WU
CHP-134 MluxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzKZoVKSzVyPUK2MlM5PjdizszN NFfpVoNUSU6JRWK=
SW962 MkX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjmOZVKSzVyPUK2MlUxOjFizszN MX;TRW5ITVJ?
SNU-449 NG\zUItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPIUWdKSzVyPUK3MlA5ODNizszN NHT4S3JUSU6JRWK=
HuP-T4 NGDYRo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGja[|lKSzVyPUK3MlA5PzlizszN M4\qeXNCVkeHUh?=
SW948 MlfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTJ5LkGzOFQh|ryP MnTmV2FPT0WU
NCI-H226 NUH3[JA1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3P2cGlEPTB;MkeuOFU4QCEQvF2= M4XzdHNCVkeHUh?=
SK-PN-DW MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7FTWM2OD1{Nz62NFEzKM7:TR?= NWrHfJVZW0GQR1XS
GI-1 NVL0U2NvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTJ5LkeyNUDPxE1? MmPqV2FPT0WU
CAL-12T MljsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfVfY9FUUN3ME2yPE4yOTF{IN88US=> MnixV2FPT0WU
YAPC MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPPTWM2OD1{OD6yOVY1KM7:TR?= M4D2eHNCVkeHUh?=
SNU-C2B MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTJ6LkK5OlQh|ryP NWLtcYs3W0GQR1XS
RCC10RGB Ml\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXP4XokzUUN3ME2yPE42PDF5IN88US=> Mn36V2FPT0WU
ES7 Mlq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYraclh5UUN3ME2yPU4yPDZ3IN88US=> NYDT[YtNW0GQR1XS
PANC-03-27 M1L2Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3TRo4zUUN3ME2yPU41PDRizszN MYPTRW5ITVJ?
ES6 NYHmOGMyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvGNpFKSzVyPUK5MlgyPTdizszN M4PEenNCVkeHUh?=
HT-1197 NYDh[4E6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV61PZZPUUN3ME2zNE4xPTl6IN88US=> NHL5OGpUSU6JRWK=
ZR-75-30 Mk\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\XXoFUUUN3ME2zNE4zOzh|IN88US=> MUfTRW5ITVJ?
DB MnLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3r2d2lEPTB;M{CuOFk1OiEQvF2= MVvTRW5ITVJ?
OCI-AML2 NIX3fm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{Dxc2lEPTB;M{GuNFY6KM7:TR?= MlPyV2FPT0WU
NCI-H2170 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF74NWFKSzVyPUOxMlg2OTZizszN MlT2V2FPT0WU
IST-MES1 M2L4S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTN{LkK4PVch|ryP MVLTRW5ITVJ?
769-P Mm\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnj4TWM2OD1|Mj6zOlQyKM7:TR?= MU\TRW5ITVJ?
COR-L23 M1z0N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFOwUZVKSzVyPUOyMlkxPzNizszN MYLTRW5ITVJ?
SW626 Ml3lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HUO2lEPTB;M{OuNVc4PiEQvF2= MVnTRW5ITVJ?
LU-139 Mn\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFX5VYJKSzVyPUOzMlY3ODVizszN NHrWOGhUSU6JRWK=
HT-144 NInlSHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTN|Lki2N{DPxE1? NFuyXJBUSU6JRWK=
CaR-1 MmLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvZTWM2OD1|Mz65PFIzKM7:TR?= M{TwWXNCVkeHUh?=
OE33 NWrKfY14T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWT4NmZVUUN3ME2zOE4zQDV3IN88US=> NHq3cG1USU6JRWK=
COLO-800 NY\YcFNXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTN2LkO2OFch|ryP NXPX[pBZW0GQR1XS
NB14 M16ybWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHwTWM2OD1|ND60Olg1KM7:TR?= NVO4SVQ{W0GQR1XS
KURAMOCHI MoXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjXR4NKSzVyPUO2MlEyQThizszN NYnNW496W0GQR1XS
SW48 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoiwTWM2OD1|Nj6yOFc1KM7:TR?= MWHTRW5ITVJ?
Daoy MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYO3UoNCUUN3ME2zOk43PTN6IN88US=> NXjLVXRuW0GQR1XS
TGBC24TKB NGTVXWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTTfXdKSzVyPUO2MlY4KM7:TR?= Ml60V2FPT0WU
DU-4475 MmfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{Lze2lEPTB;M{[uPVA{OyEQvF2= NUHZSWljW0GQR1XS
SW1417 NVTO[mlkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;CSnlKSzVyPUO4MlA2PTJizszN NVn3VlNGW0GQR1XS
EFO-21 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LD[mlEPTB;M{iuPVM1QSEQvF2= MkLPV2FPT0WU
MG-63 M1rWWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rWVGlEPTB;M{muN|QzPCEQvF2= MVLTRW5ITVJ?
LC-2-ad MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{i4eWlEPTB;M{muOVUyOiEQvF2= MWXTRW5ITVJ?
NOMO-1 NWTJ[4NNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonnTWM2OD1|OT64Nlc1KM7:TR?= NYLnSmRUW0GQR1XS
COLO-741 M{G3bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTRyLkGzNFQh|ryP NFOxWXNUSU6JRWK=
BxPC-3 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PKUmlEPTB;NECuOVY5PiEQvF2= M4rlbXNCVkeHUh?=
HSC-2 M1TDNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvnO21KSzVyPUSwMlkyOTNizszN MojuV2FPT0WU
UMC-11 M4f0XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;hTWM2OD12MT6yOlMh|ryP NUn3TZhRW0GQR1XS
HCC1937 NEPaZXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jtXGlEPTB;NEKuO|g1OyEQvF2= MX;TRW5ITVJ?
Calu-6 M3XvUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nwUmlEPTB;NEOuNlM5OiEQvF2= MX\TRW5ITVJ?
NCI-H1573 MlLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnmzTWM2OD12Mz6zOFc4KM7:TR?= M33lWHNCVkeHUh?=
SK-N-AS MkL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjOZ4xKSzVyPUSzMlYxOTlizszN M1HidXNCVkeHUh?=
PSN1 NVPHRlBQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TobWlEPTB;NEWuNlU1QCEQvF2= NYTtN5p[W0GQR1XS
TE-11 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLaTWM2OD12NT60PFQzKM7:TR?= MmPGV2FPT0WU
NCI-H1155 NWHsZXcyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDkTWM2OD12NT64PVY4KM7:TR?= M1i3SXNCVkeHUh?=
KM12 M{faRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTR3LkmwO|Yh|ryP MXzTRW5ITVJ?
RO82-W-1 MkDqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTR4Lkm4NlIh|ryP M{f3WXNCVkeHUh?=
SW1573 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfGTWM2OD12Nz6zO|M3KM7:TR?= Mk\CV2FPT0WU
CAKI-1 NUn4b3FHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37XdmlEPTB;NEiuNlg1PSEQvF2= Mlm4V2FPT0WU
U-118-MG NY\YOnFqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTR6LkO3NFIh|ryP M1jUc3NCVkeHUh?=
KYSE-520 NGPUOJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LHeWlEPTB;NEiuOFAyPiEQvF2= MWfTRW5ITVJ?
HT55 M1;4Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXiyT|JoUUN3ME20PU4yPDd2IN88US=> M2G4WHNCVkeHUh?=
ChaGo-K-1 NEDnVZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPPTWM2OD12OT60O|k{KM7:TR?= MWnTRW5ITVJ?
IA-LM M1PRXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1O5cWlEPTB;NUSuOlMzOiEQvF2= M1rxfHNCVkeHUh?=
UACC-62 MlPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\XTWM2OD13NT6xNFQ3KM7:TR?= NUjLXHFnW0GQR1XS
MKN7 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\uRoxHUUN3ME21Ok4xOjh3IN88US=> M1LLdnNCVkeHUh?=
HPAF-II Ml6zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYja[nNwUUN3ME21Ok41ODd|IN88US=> MXjTRW5ITVJ?
NTERA-S-cl-D1 NV;jR|R4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHneoFKSzVyPUW3Mlc4QCEQvF2= MYrTRW5ITVJ?
FTC-133 NHfBXYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnDRXFOUUN3ME21PE4xQTZ7IN88US=> MYDTRW5ITVJ?
MHH-ES-1 NXzxRZgyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTV6LkS4NVQh|ryP NGPvTmxUSU6JRWK=
JVM-2 NVXyOHBUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1SyRWlEPTB;NUiuPVUxPiEQvF2= MYLTRW5ITVJ?
TCCSUP MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPHZZdKSzVyPUW5MlUzPzlizszN M{LQcXNCVkeHUh?=
COLO-824 M{fROmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPHTm1PUUN3ME22NE4xPzF7IN88US=> MoW5V2FPT0WU
647-V NHP6O5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XU[mlEPTB;NkCuNVM1PyEQvF2= M{DEWnNCVkeHUh?=
HD-MY-Z MnuyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTZyLkWyPVQh|ryP M1qzS3NCVkeHUh?=
LS-411N M3LVbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTZzLkO5NFMh|ryP NHzXUYRUSU6JRWK=
NCI-H596 M1vMPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTZ{Lke0PVYh|ryP NYXofZY1W0GQR1XS
C-33-A M4nmNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnCTWM2OD14ND6wPVU4KM7:TR?= NFH4SolUSU6JRWK=
BHY M3zN[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzGRWdKSzVyPU[0MlEzPDVizszN NH[zV49USU6JRWK=
KGN MkPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWruVWFFUUN3ME22OE42PTF2IN88US=> MnviV2FPT0WU
NCI-H1092 NGTnR|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEe2XXFKSzVyPU[1MlAxQTVizszN NYDub|J6W0GQR1XS
MZ1-PC NIi4UGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTZ3LkW2OFkh|ryP NHztN3JUSU6JRWK=
LB831-BLC MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfsfW5KSzVyPU[1Mlg1QDFizszN NHjCSmNUSU6JRWK=
SW620 NWX4WoQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTZ4LkKwN|kh|ryP NXLMfIpXW0GQR1XS
HuO-3N1 MofXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\HSWlEPTB;NkiuN|I{QCEQvF2= MWHTRW5ITVJ?
SK-HEP-1 M3HYNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTZ7Lkm0PFYh|ryP MlXRV2FPT0WU
LCLC-103H M13Jd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1X5XWlEPTB;N{CuOlcxPSEQvF2= MU\TRW5ITVJ?
KYSE-70 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWraPIR{UUN3ME23NE44QDN3IN88US=> NHWySZZUSU6JRWK=
Mewo NGfxNllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\WVGRoUUN3ME23NU42ODVizszN Mln0V2FPT0WU
COLO-668 MkL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXyOYZKSzVyPUexMlg1PTFizszN NFftRVJUSU6JRWK=
NCI-H522 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;qbJFSUUN3ME23Nk4{PDF|IN88US=> NWj2U3FQW0GQR1XS
NCI-H1437 NIfjZVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDPNnRKSzVyPUe0MlQxPDhizszN NGezd2FUSU6JRWK=
U-266 Ml;VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTd3LkS1NVYh|ryP Mm\KV2FPT0WU
MC116 NX;MR3g5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTd3LkW3NFgh|ryP M2SxXXNCVkeHUh?=
PANC-10-05 NGXCVHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnqwTWM2OD15Nz60NlQ{KM7:TR?= M3fPbHNCVkeHUh?=
KYSE-180 M2Hrcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHTTWM2OD15Nz61OFU1KM7:TR?= NX3mN5k3W0GQR1XS
JAR M3\BeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrWPZRKSzVyPUe5MlA2PDZizszN NX[1UoZxW0GQR1XS
CAL-62 M3\WdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTBTWM2OD16MD6wPVUh|ryP MYHTRW5ITVJ?
A3-KAW MoG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoD2TWM2OD16MD6yNVU1KM7:TR?= M{L4UHNCVkeHUh?=
PANC-08-13 NInabWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRThzLkG3Olgh|ryP MkT0V2FPT0WU
HSC-3 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHDUZZKSzVyPUizMlMxPzFizszN NGSxVIxUSU6JRWK=
HTC-C3 NX[1bIdrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzETWM2OD16Mz60O|AzKM7:TR?= NWCzR3psW0GQR1XS
KY821 NXm4PJdmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3z0bWlEPTB;OESuNFg6OiEQvF2= NULmSW9JW0GQR1XS
DoTc2-4510 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzDTWM2OD16ND6yNVg2KM7:TR?= MYXTRW5ITVJ?
NCI-H1581 MlH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHL4[ZRKSzVyPUi1MlQ3PDFizszN MWTTRW5ITVJ?
KARPAS-299 M4XDT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDqTWM2OD16Nj6xPVc4KM7:TR?= MkPWV2FPT0WU
IST-MEL1 NVvKdoxHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\pNmlEPTB;OE[uPFg4OiEQvF2= M4LxfHNCVkeHUh?=
KP-N-YS NYnEVmgyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGewZYFKSzVyPUi5MlkxOjhizszN M1WwfnNCVkeHUh?=
KYSE-410 MmPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2T6VmlEPTB;OUGuOFA1OiEQvF2= MnXRV2FPT0WU
TE-10 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3ZTWM2OD17MT61OlEyKM7:TR?= M2DqOHNCVkeHUh?=
SK-MEL-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3JTWM2OD17Mj65NVA3KM7:TR?= MWrTRW5ITVJ?
COLO-792 MlOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnMTWM2OD17NT6yOVY1KM7:TR?= M2GxWnNCVkeHUh?=
SCH M3;UfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTl4LkO4O|ch|ryP NXrCTJd5W0GQR1XS
NCI-H1792 M{PqSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3f6ZmlEPTB;OU[uPFk6OiEQvF2= NHj6cFFUSU6JRWK=
NCI-H2029 NI\E[2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTzTWM2OD17Nj65OVY3KM7:TR?= MUXTRW5ITVJ?
SW684 MlzKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX22XHFxUUN3ME25PE43PjV2IN88US=> NVm5UllIW0GQR1XS
NCI-H209 NG\5OoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvEdFdKSzVyPUGwNE4yOjFizszN NXXkWGFuW0GQR1XS
HLE M2XNZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXETWM2OD1zMEWuNlgzKM7:TR?= MnfMV2FPT0WU
GOTO MnOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DCTmlEPTB;MUC3Mlc4PyEQvF2= M1jXcXNCVkeHUh?=
NCI-H1793 NUjhW|VlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\MTWM2OD1zMEmuNlgh|ryP NXy3cpJJW0GQR1XS
D-392MG NYewNppkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13ycmlEPTB;MUG3MlM6QCEQvF2= NIfuWYtUSU6JRWK=
SW1990 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\NTWM2OD1zMkCuPVUyKM7:TR?= M2TZWHNCVkeHUh?=
ML-2 NYXSW5JVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTiTWM2OD1zMkGuOlc3KM7:TR?= NYrZb2JDW0GQR1XS
NCI-H2452 M4jqO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofTTWM2OD1zMkKuNlEh|ryP MUjTRW5ITVJ?
SK-MEL-30 NITBdpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTF{Mz6yOFQh|ryP NFroXlNUSU6JRWK=
SN12C NUHie|ljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LYTmlEPTB;MUK0MlE4PiEQvF2= NXv6O5lvW0GQR1XS
NCI-H1770 NIDZdZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3hSHFKSzVyPUGyOU42OTRizszN M{Hr[3NCVkeHUh?=
SF268 NYDtXpF3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlv2TWM2OD1zMk[uNVU5KM7:TR?= M3nqcHNCVkeHUh?=
BALL-1 NFjHVIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTF{Nj6yN{DPxE1? M376XnNCVkeHUh?=
COLO-679 M{jPfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPjTWM2OD1zMk[uO|U{KM7:TR?= MVLTRW5ITVJ?
A2780 M{DiRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTF{OD65PFgh|ryP NV7nWIRVW0GQR1XS
NCI-H1651 NILUSo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTF|MT6yOFMh|ryP M2PXUXNCVkeHUh?=
NCI-H2087 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPOTWM2OD1zM{GuOFg{KM7:TR?= NFTzXoJUSU6JRWK=
U-87-MG MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HGbmlEPTB;MUOzMlYxPCEQvF2= NGTEW4xUSU6JRWK=
LB2518-MEL NED0PWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlv4TWM2OD1zM{WuPVk{KM7:TR?= MXnTRW5ITVJ?
HCT-116 MnLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnW3TWM2OD1zM{euNlE4KM7:TR?= NXO2NIdQW0GQR1XS
Ca9-22 NUPIV49KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrQWlNKSzVyPUGzPU45OzNizszN NXrseFF2W0GQR1XS
COR-L88 NXr2RYR4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzMdllvUUN3ME2xOFIvOTRizszN Mm\5V2FPT0WU
CP50-MEL-B NVrxfoN[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnLbFFKSzVyPUG0OE42ODFizszN NFThWVdUSU6JRWK=
OVCAR-8 NIf1V5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYn5OZBLUUN3ME2xOFUvPjN4IN88US=> MVjTRW5ITVJ?
SK-MEL-3 NXntOWE3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTF2Nz64O|gh|ryP NYTRRWtVW0GQR1XS
GT3TKB NUnuN|l7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vPW2lEPTB;MUS5MlkzQCEQvF2= MlrlV2FPT0WU
KYSE-450 NVHscY16T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\JPGM6UUN3ME2xOVEvPTN7IN88US=> MXTTRW5ITVJ?
CAPAN-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XremlEPTB;MUWzMlA3PCEQvF2= MXTTRW5ITVJ?
BEN MkHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnFcHlJUUN3ME2xOVMvQTJ6IN88US=> NIT6O5lUSU6JRWK=
NCI-H1304 NYPKd4VqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TGUGlEPTB;MUW0MlY6PCEQvF2= MV\TRW5ITVJ?
KU812 MoHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHWyOnFKSzVyPUG1PE43PzRizszN Mnq4V2FPT0WU
Capan-2 M{HC[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTF4MD61OVMh|ryP NXHt[mdrW0GQR1XS
A673 NH\BVmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTF4MT63NFUh|ryP MnrzV2FPT0WU
SAS NEi0dXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGf1cFNKSzVyPUG2Nk43PzhizszN NVP1XHI4W0GQR1XS
NY NVXqWVRLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYn6e4hmUUN3ME2xOlUvOzF2IN88US=> Mmi2V2FPT0WU
HCE-4 MmnKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3pUZVmUUN3ME2xOlYvQDR3IN88US=> M3TI[HNCVkeHUh?=
MDA-MB-231 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzRfWhmUUN3ME2xO|cvPTB|IN88US=> NVe3bnhNW0GQR1XS
no-10 M3HoS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLPbGsxUUN3ME2xO|gvOTN2IN88US=> NWDYOmtYW0GQR1XS
MZ7-mel MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrJNpUyUUN3ME2xO|gvPDZ5IN88US=> M{f0R3NCVkeHUh?=
NCI-H82 M4LlR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2O3VmlEPTB;MUiwMlE3PSEQvF2= NYnzdWVYW0GQR1XS
CAL-72 MlHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NED2NXpKSzVyPUG4OU4xPTRizszN NEmwTmRUSU6JRWK=
NCI-SNU-5 MnTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEW2W45KSzVyPUG4Ok45PCEQvF2= NYD2cFBxW0GQR1XS
OVCAR-4 M3;DcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFT3N2dKSzVyPUG4PE4{OzNizszN NIfS[4pUSU6JRWK=
SCC-9 NInz[G1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MluwTWM2OD1zOUGg{txO NWrWO2NwW0GQR1XS
KYSE-150 NG\NSJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTF7MT64PFgh|ryP MWHTRW5ITVJ?
HT-29 M2DscGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY[3dJB5UUN3ME2yNFEvOjF{IN88US=> NYjYWXY5W0GQR1XS
COLO-678 M1LqWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkT3TWM2OD1{MEGuOFUh|ryP NHKxVW1USU6JRWK=
NCI-H650 M2\M[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnGwTWM2OD1{MEKuNVA{KM7:TR?= NH;YVo5USU6JRWK=
HuCCT1 NIHvWWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jBcGlEPTB;MkC0MlIxQCEQvF2= MVfTRW5ITVJ?
SW1116 NYHqNWtMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7Rc3RKSzVyPUKwO{4xPzdizszN MXHTRW5ITVJ?
DBTRG-05MG MonYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;rOHVNUUN3ME2yNFcvQTB7IN88US=> NHXqWmVUSU6JRWK=
SW982 NIq0fIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX[4Z4ZzUUN3ME2yNFcvQTR6IN88US=> MULTRW5ITVJ?
RCM-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TxdGlEPTB;MkG0Mlc3OiEQvF2= NHjFVnFUSU6JRWK=
COLO-320-HSR Mn7NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjYSIZYUUN3ME2yNVYvOTJ3IN88US=> NHrWWopUSU6JRWK=
KNS-42 M3W2Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{juWWlEPTB;MkG2MlU4PCEQvF2= NWfxT2Z4W0GQR1XS
C2BBe1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LOWWlEPTB;MkOxMlkxPSEQvF2= NFfhc45USU6JRWK=
CCRF-CEM MnvXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTJ2Mz63PVUh|ryP NWjxXYliW0GQR1XS
SH-4 NGnqOHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVS2dXRHUUN3ME2yOFYvODlizszN MWjTRW5ITVJ?
LS-1034 NX;qV2htT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDOPWRKSzVyPUK0Ok4zPjZizszN NHPvO5FUSU6JRWK=
NCI-H2347 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnS4TWM2OD1{NEeuO|E{KM7:TR?= MVjTRW5ITVJ?
RPMI-8866 M{i2TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3i0bWlEPTB;MkS5MlI4KM7:TR?= M{fJXXNCVkeHUh?=
GAK MlX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{[yU2lEPTB;MkWzMlAxOiEQvF2= NGjVOohUSU6JRWK=
NB6 NHvOZ3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfRcVk2UUN3ME2yO|AvOSEQvF2= NI\G[5JUSU6JRWK=
COLO-680N NVThPHU6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4[4dmlEPTB;MkeyMlUzPyEQvF2= MVrTRW5ITVJ?
RERF-LC-MS M3XFOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jyXWlEPTB;Mke2MlAxPyEQvF2= MVXTRW5ITVJ?
TGBC11TKB NGPMPYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTJ5OD6xO|gh|ryP NGTtOJhUSU6JRWK=
C8166 NGnQNItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTJ5OD61NFYh|ryP M{XGb3NCVkeHUh?=
HDLM-2 NX;K[VUxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTJ7ND60NFkh|ryP NUPmUFZsW0GQR1XS
IGR-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vZSmlEPTB;Mkm1MlY2QSEQvF2= MX;TRW5ITVJ?
FADU MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTJ7Nz61NUDPxE1? MXrTRW5ITVJ?
L-428 MnO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHYTohmUUN3ME2yPVcvPjF4IN88US=> MlfKV2FPT0WU
LU-65 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\MeFJZUUN3ME2zNFQvOzJizszN M2GxN3NCVkeHUh?=
HEL M{HvR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3uRnVNUUN3ME2zNFkvQTh|IN88US=> MWPTRW5ITVJ?
NCI-H810 NIX4UoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXLXlJuUUN3ME2zNVAvPTdizszN NFrJR4FUSU6JRWK=
C3A MlnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PBb2lEPTB;M{GxMlgxOiEQvF2= MUDTRW5ITVJ?
NCI-H630 M3nL[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnHVFBKSzVyPUOzNk4zQTRizszN NV;EW5RIW0GQR1XS
KP-N-YN M{XEWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvMNJpKSzVyPUO0NU4yOjNizszN NWjPbY5pW0GQR1XS
MOLT-13 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LubWlEPTB;M{SyMlMzPiEQvF2= NF72Z25USU6JRWK=
NCI-H1993 M1;0WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTN2Mj6zOlUh|ryP Mk\RV2FPT0WU
BE-13 M13WV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTN2ND6xOlch|ryP NX6wdHFqW0GQR1XS
IST-SL1 M4K1TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIC1dGFKSzVyPUO0O{41ODFizszN MWLTRW5ITVJ?
TE-9 M3;YUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWX0TnJFUUN3ME2zOlMvPTh7IN88US=> MmToV2FPT0WU
LU-135 NF;KZ4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrpVnlKSzVyPUO2O{4xOzVizszN MkXBV2FPT0WU
T84 Mo\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTN5ND63NVIh|ryP M3HGTnNCVkeHUh?=
K-562 MnzSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\WVGtkUUN3ME2zPFMvOzZizszN M1vHbHNCVkeHUh?=
SBC-5 NXH6c|ZlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTN6Nj65PFUh|ryP NFTQepVUSU6JRWK=
NB17 NVLDRWxtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPGTmJKSzVyPUO5Nk42QTZizszN M4TvcnNCVkeHUh?=
NCI-H2052 M3HCWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTN7OD60O|Ih|ryP NEW1V2lUSU6JRWK=
HCC38 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFG0fVBKSzVyPUSwNU42QTNizszN NWTySpNkW0GQR1XS
NCI-H69 M1qyeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIricnVKSzVyPUS0NU4xQDNizszN M37M[HNCVkeHUh?=

... Click to View More Cell Line Experimental Data
In vivo MK-2206 shows 60% TGI and inhibits more than 70 % of phospho-Akt1/2 (T308 and S473) in A2780 ovarian cancer xenografts at a dose of 240 mg/kg. [1] MK-2206 exhibits significant antitumor activity in NCI-H292 xenograft in combination with erlotinib or lapatinib. [2]

Protocol

Kinase Assay:

[4]
+ Expand

Akt kinases assay:

Akt kinases are assayed by a GSK-derived biotinylated peptide substrate. The extent of peptide phosphorylation is determined by Homogeneous Time Resolved Fluorescence (HTRF) using a lanthanide chelate (Lance)-coupled monoclonal antibody specific for the phosphopeptide in combination with a streptavidin-linked allophycocyanin (SA-APC) fluorophore which will bind to the biotin moiety on the peptide. When the Lance and APC are in proximity, a non-radiative energy transfer takes place from the Lance to the APC, followed by emission of light from APC at 655 nm. Working Solution: 100X protease inhibitor cocktail (PIC): 1mg/mL benzamidine, 0.5 mg/mL pepstatin, 0.5 mg/mL leupeptin, 0.5 mg/mL aprotinin; 10X assay buffer: 500 mM HEPES, pH7.5, 1% PEG, 16.6 mM EDTA, 1 mM EGTA, 1% BSA, 20 mM 9-glycerol phosphate; Quench buffer 50 mM HEPES pH 7.3, 16.6 mM EDTA, 0.1% BSA, 0.1% Triton X-100, 0.17 nM labeled monoclonal antibody, 0.0067 mg/mL SA-APC; ATP/MgCl2 working solution: 1X Assay buffer, 1 mM DTT, 1X PIC, 5% glycerol, active Akt; Peptide working solution: 1X Assay buffer, 1 mM DTT, 1X PIC, 5% glycerol, 2 TM GSK biotinylated peptide. The reaction is assembled by adding 16 µL of ATP/MgCl2 working solution to the appropriate wells. MK-2206 or vehicle (1.0 µL) is added followed by 10 µL of peptide working solution. The reaction is started by adding 13 μL of the enzyme working solution and mixing. The reaction is allowed to proceed for 50 min and then stopped by the addition of 60 µL HTRF quench buffer. The stopped reactions are incubated at room temperature for at least 30 min and then read in the instrument.
Cell Research:

[2]
+ Expand
  • Cell lines: A431, HCC827, NCI-H292, NCI-H358, NCI-H23, NCI-H1299, Calu-6 and NCI-H460 cells
  • Concentrations: 0, 0.3, 1 and 3 μM
  • Incubation Time: 72 or 96 hours
  • Method:

    MK-2206 is dissolved in DMSO as a stock solution and diluted by culture media before use. Cells are seeded at a density of 2-3 × 103 in 96-well plates and incubated for 24 hours. Then MK-2206 (0, 0.3, 1 and 3 μM) is added to the cells. Cell proliferation is determined after 72 or 96 hours.


    (Only for Reference)
Animal Research:

[2]
+ Expand
  • Animal Models: SK-OV-3, NCI-H292, HCC70, PC-3, and NCI-H460 models in male CD1-nude mice
  • Formulation: Formulated in 30% Captisol
  • Dosages: 120 mg/kg
  • Administration: Orally administered
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 14 mg/mL (29.14 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
15% Captisol
For best results, use promptly after mixing. 		17 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 480.39
Formula

C25H21N5O.2HCl
CAS No. 1032350-13-2
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01802320 Active not recruiting Colon Mucinous Adenocarcinoma|Colon Signet Ring Cell Adenocarcinoma|Rectal Mucinous Adenocarcinoma|Rectal Signet Ring Cell Adenocarcinoma|Recurrent Colon Carcinoma|Recurrent Rectal Carcinoma|Stage IIIA Colon Cancer|Stage IIIA Rectal Cancer|Stage IIIB Colon Cancer|Stage IIIB Rectal Cancer|Stage IIIC Colon Cancer|Stage IIIC Rectal Cancer|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer National Cancer Institute (NCI) March 2013 Phase 2
NCT01859182 Withdrawn Adenocarcinoma of the Gallbladder|Adenocarcinoma With Squamous Metaplasia of the Gallbladder|Adult Primary Cholangiocellular Carcinoma|Advanced Adult Primary Liver Cancer|Cholangiocarcinoma of the Extrahepatic Bile Duct|Localized Unresectable Adult Primary Liver Cancer|Metastatic Extrahepatic Bile Duct Cancer|Recurrent Adult Primary Liver Cancer|Recurrent Extrahepatic Bile Duct Cancer|Stage II Gallbladder Cancer|Stage IIIA Gallbladder Cancer|Stage IIIB Gallbladder Cancer|Stage IVA Gallbladder Cancer|Stage IVB Gallbladder Cancer|Unresectable Extrahepatic Bile Duct Cancer National Cancer Institute (NCI) January 2013 Phase 2
NCT01783171 Completed Pancreatic Adenocarcinoma|Recurrent Pancreatic Carcinoma|Stage III Pancreatic Cancer AJCC v6 and v7|Stage IV Pancreatic Cancer AJCC v6 and v7|Unresectable Pancreatic Carcinoma National Cancer Institute (NCI) January 15 2013 Phase 1
NCT01776008 Terminated Estrogen Receptor Positive|HER2/Neu Negative|Recurrent Breast Carcinoma|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer National Cancer Institute (NCI) January 2013 Phase 2
NCT01705340 Terminated Adenocarcinoma of the Gastroesophageal Junction|HER2-positive Breast Cancer|Male Breast Cancer|Recurrent Breast Cancer|Recurrent Esophageal Cancer|Recurrent Gastric Cancer|Stage IIIC Breast Cancer|Stage IIIC Esophageal Cancer|Stage IIIC Gastric Cancer|Stage IV Breast Cancer|Stage IV Esophageal Cancer|Stage IV Gastric Cancer National Cancer Institute (NCI) September 2012 Phase 1
NCT01658943 Completed Pancreatic Acinar Cell Carcinoma|Pancreatic Ductal Adenocarcinoma|Recurrent Pancreatic Carcinoma|Stage IV Pancreatic Cancer National Cancer Institute (NCI) August 2012 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What is your recommendation for preparing the solution and how would you deliver it to the mice (i.p. or gavage)?

  • Answer:

    You can resuspend MK-2206 in 15% Captisol at up to 17mg/ml. It's a suspension and is for oral gavage use only.

  • Question 2:

    I would want to know if MK-2206 could cross the blood brain barrier?

  • Answer:

    MK-2206 can cross BBB based on the following reference: https://clinicaltrials.gov/ct2/show/NCT01249105.

selleck catalog

Akt Signaling Pathway Map

Akt Inhibitors with Unique Features

  • Selective Akt Inhibitor

    CCT128930 : AKT2-selective, IC50=6 nM.

  • Most Potent Akt Inhibitor

    AZD5363 : Akt1, IC50=3 nM; Akt2, IC50=8 nM; Akt3, IC50=8 nM.

  • Akt Inhibitor in Clinical Trial

    Perifosine (KRX-0401) : Phase III fro relapsed and refractory multiple myeloma.

  • Newest Akt Inhibitor

    AZD5363 : Potent inhibitor of all isoforms of Akt (Akt1/Akt2/Akt3) with IC50 of 3 nM/8 nM/8 nM, similar to P70S6K/PKA and lower activity towards ROCK1/2.

Related Akt Products4

  • Afuresertib (GSK2110183) New

    Afuresertib (GSK2110183) is a potent, orally bioavailable Akt inhibitor with Ki of 0.08 nM, 2 nM, and 2.6 nM for Akt1, Akt2, and Akt3, respectively. Phase 2.

  • AT13148 New

    AT13148 is an oral, ATP-competitive, multi-AGC kinase inhibitor with IC50 of 38 nM/402 nM/50 nM, 8 nM, 3 nM, and 6 nM/4 nM for Akt1/2/3, p70S6K, PKA, and ROCKI/II, respectively. Phase 1.

  • SC79 New

    SC79 is a brain-penetrable Akt phosphorylation activator and an inhibitor of Akt-PH domain translocation.

  • Capivasertib (AZD5363)

    AZD5363 potently inhibits all isoforms of Akt(Akt1/Akt2/Akt3) with IC50 of 3 nM/8 nM/8 nM in cell-free assays, similar to P70S6K/PKA and lower activity towards ROCK1/2. Phase 2.

    Features:Moderate preclinical tolerability, and PD characteristics of an AKT inhibitor. Distinct profile from other AKT inhibitors in clinical development.

  • Ipatasertib (GDC-0068)

    Ipatasertib (GDC-0068) is a highly selective pan-Akt inhibitor targeting Akt1/2/3 with IC50 of 5 nM/18 nM/8 nM in cell-free assays, 620-fold selectivity over PKA. Phase 2.

  • GSK690693

    GSK690693 is a pan-Akt inhibitor targeting Akt1/2/3 with IC50 of 2 nM/13 nM/9 nM in cell-free assays, also sensitive to the AGC kinase family: PKA, PrkX and PKC isozymes. Phase 1.

  • Perifosine (KRX-0401)

    Perifosine (KRX-0401) is a novel Akt inhibitor with IC50 of 4.7 μM in MM.1S cells, targets pleckstrin homology domain of Akt. Phase 3.

  • A-674563

    A-674563 is an Akt1 inhibitor with Ki of 11 nM in cell-free assays, modest potent to PKA and >30-fold selective for Akt1 over PKC.

    Features:Orally bioavailable compound (achieved by replacing indole of A-443654 with phenyl moiety) and somewhat less selective for Akt over PKA than A-443654.

  • Triciribine

    Triciribine is a DNA synthesis inhibitor, also inhibits Akt in PC3 cell line and HIV-1 in CEM-SS, H9, H9IIIB, U1 cells with IC50 of 130 nM and 20 nM, respectively; does not inhibit PI3K/PDK1; 5000-fold less active in cells lacking adenosine kinase. Phase 1/2.

  • Honokiol

    Honokiol is the active principle of magnolia extract that inhibits Akt-phosphorylation and promotes ERK1/2 phosphorylation. Phase 3.

Tags: buy MK-2206 2HCl | MK-2206 2HCl supplier | purchase MK-2206 2HCl | MK-2206 2HCl cost | MK-2206 2HCl manufacturer | order MK-2206 2HCl | MK-2206 2HCl distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID